PrEP

Scientists say ring containing pre-exposure prophylaxis and Truvada is safe in US teens, now need data in African adolescent girls.

Long-acting HIV medications could solve problems with adherence, reduce costly laboratory tests to monitor their efficacy, and bring down drug costs.

PrEP has been found to be effective in preventing HIV in high-risk populations.

Increasingly, individuals with HIV also have comorbid conditions, such as cardiovascular disease, hypertension, and diabetes.

New diagnoses and prevalence of HIV is illustrated by demographics, location, and social determinants of health.

More than 1.1 million Americans are HIV-positive, yet 15% are unaware of their status.

A number of hurdles in HIV, including preventative efforts, still need to be addressed.

Screening for drug interactions is a challenge when a patient with HIV presents with several prescriptions.

HIV clinical staff should ask questions about each patient’s relationships and sexual activity regularly and redundantly.

The drug is indicated as a combination treatment of HIV and for pre-exposure prophylaxis.

FDA approves first generic version of emtricitabine and tenofovir disoproxil fumarate (Truvada).

There are few shortcuts that address the large number of medications and different treatment regimens that are needed to treat patients with HIV.

Patients with HIV can now expect to live into old age, and therefore need links to the community health network.

Scientists project combining prevention programs could avert up to 40,000 HIV infections over 20 years among injection drug users.

HIV infection may affect cognition in young patients.

Continuing ART post-delivery shows benefits in women with early stage HIV,

Patients with HIV have nearly twice the risk of ischemic heart disease, heart failure, and myocardial infection.

As patients with HIV age, they develop chronic conditions associated with older age and take more medication.

HIV has become a chronic disease that requires a different strategy with aging patients.

Data discusses the unique issues senior patients with HIV face.

The risk of comorbid chronic obstructive pulmonary disorder in patients infected with HIV may be underestimated.

Study provides first direct evidence of HIV persistence in tissue macrophages in vivo, which could lead to a cure for HIV.

Pitavastatin reduced LDL cholesterol with little impact on HIV-1 RNA and CD4 cell counts.

Pitavastatin lowered LDL cholesterol levels in patients with HIV and dyslipidemia.

Nearly 70% of patients with HIV take dietary supplements with their antiretroviral therapy.